P/E ratio for Oramed Pharmaceuticals (ORMP)
P/E ratio as of May 2024 (TTM): -4.57
According to Oramed Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.56863. At the end of 2022 the company had a P/E ratio of -12.8.
P/E ratio history for Oramed Pharmaceuticals from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -12.8 | -30.99% |
| 2021 | -18.5 | 188.68% |
| 2020 | -6.42 | -10.19% |
| 2019 | -7.15 | 121.74% |
| 2018 | -3.23 | -72.4% |
| 2017 | -11.7 | 64.25% |
| 2016 | -7.12 | -41.74% |
| 2015 | -12.2 | 76.79% |
| 2014 | -6.91 | -74.03% |
| 2013 | -26.6 | 323.24% |
| 2012 | -6.29 | |
| 2010 | -6.00 | -46.67% |
| 2009 | -11.3 | 130.77% |
| 2008 | -4.87 | 68.75% |
| 2007 | -2.89 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novo Nordisk NVO | 46.6 | -1,119.70% | 🇩🇰 Denmark |
 Sanofi SNY | 15.4 | -436.01% | 🇫🇷 France |
 Ultragenyx RARE | -4.16 | -8.92% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | -2.71 | -40.77% | 🇺🇸 USA |
 Compugen CGEN | -5.35 | 17.10% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.